[go: up one dir, main page]

WO2008140565A3 - Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis - Google Patents

Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis Download PDF

Info

Publication number
WO2008140565A3
WO2008140565A3 PCT/US2007/084140 US2007084140W WO2008140565A3 WO 2008140565 A3 WO2008140565 A3 WO 2008140565A3 US 2007084140 W US2007084140 W US 2007084140W WO 2008140565 A3 WO2008140565 A3 WO 2008140565A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
necrosis factor
factor receptor
polypeptides
tumor necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/084140
Other languages
French (fr)
Other versions
WO2008140565A2 (en
Inventor
Brian A Fox
James L Holloway
Paul O Sheppard
Stacey R Dillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of WO2008140565A2 publication Critical patent/WO2008140565A2/en
Anticipated expiration legal-status Critical
Publication of WO2008140565A3 publication Critical patent/WO2008140565A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and immunity such as separating resting from stimulated immune cells.
PCT/US2007/084140 2006-11-08 2007-11-08 Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis Ceased WO2008140565A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86486406P 2006-11-08 2006-11-08
US60/864,864 2006-11-08

Publications (2)

Publication Number Publication Date
WO2008140565A2 WO2008140565A2 (en) 2008-11-20
WO2008140565A3 true WO2008140565A3 (en) 2009-06-11

Family

ID=40002800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084140 Ceased WO2008140565A2 (en) 2006-11-08 2007-11-08 Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis

Country Status (1)

Country Link
WO (1) WO2008140565A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582815A (en) 2007-08-03 2012-07-27 Abbott Biotherapeutics Corp Therapeutic use of anti- tweak receptor antibodies to treat cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037865A2 (en) * 2003-10-16 2005-04-28 Zymogenetics, Inc. Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037865A2 (en) * 2003-10-16 2005-04-28 Zymogenetics, Inc. Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGGARWAL B B ET AL: "TNF blockade: An inflammatory issue", 56TH INTERNATIONAL WORKSHOP ON CYTOKINES AS POTENTIAL THERAPEUTIC TARGETS FOR INFLAMMATORY SKIN DISE; SAN FRANCISCO, CA, USA; NOVEMBER 17 -19, 2004,, 1 January 2006 (2006-01-01), pages 161 - 186, XP009115475, ISBN: 978-3-540-25427-0 *
FIDALGO A ET AL: "Etanercept for psoriasis: Two case reports", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, BIOSCIENCE EDIPRINT, GENEVA, CH, vol. 25, no. 4, 1 January 2005 (2005-01-01), pages 159 - 163, XP009115472, ISSN: 0251-1649 *

Also Published As

Publication number Publication date
WO2008140565A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2005080429A3 (en) Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
TW200631594A (en) Toll like receptor 3 antagonists, methods and uses
IL173559A0 (en) Nogo receptor antagonists
MX2009002571A (en) Anti-activin a antibodies and uses thereof.
MX2008009886A (en) Antibodies that bind par-2.
IL245462A0 (en) Humanized anti-cmet antagonists
WO2005005462A3 (en) Blys antagonists and uses thereof
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
EA201500316A1 (en) Antagonists of toll-like receptor 3
IL163067A (en) Isolated heterodimeric cytokine receptor
MXPA05011409A (en) Compositions and methods for the therapy of inflammatory bowel disease.
PL380274A1 (en) Nogo receptor antagonists
WO2007051164A3 (en) Toll like receptor 3 modulators, methods and uses
EA201171307A1 (en) Antagonists of toll-like receptor 3
WO2008067305A3 (en) Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
MY145281A (en) Novel compounds
WO2007059190A3 (en) Compositions of and methods of using stabilized psma dimers
WO2008140565A3 (en) Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis
WO2005037865A3 (en) Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR
WO2003044162A3 (en) Genes encoding g-protein coupled receptors and methods of use therefor
EP1212340A4 (en) 29 human cancer associated proteins
WO2003059281A3 (en) Novel variants of rankl protein
EP1789452A4 (en) Relaxin-chimeric polypeptides and their preparation and use

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874261

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07874261

Country of ref document: EP

Kind code of ref document: A2